Valganciclovir
Disease Related To Transplantation
Explore 14 assets in Disease Related To Transplantation →Floatz Rating
B57/100
Confidence
Indicative
Sponsor
Fernanda P Silveira, MD, MS
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
42Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05041426CT.gov Letermovir for CMV Prevention After Lung Transplantation | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Disease Related To Transplantation
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Valganciclovir (this asset) | Fernanda P Silveira, MD, MS | P2 | B · 57 |
| Tacrolimus | University of Illinois at Chicago | P4 | BBB |
| Cyclosporin A | Fernanda P Silveira, MD, MS | P4 | BBB |
| Sirolimus | Wyeth is now a wholly owned subsidiary of Pfizer | P4 | BBB |
| Busulfanum | M.D. Anderson Cancer Center | P3 | BB |
| Fludarabine | M.D. Anderson Cancer Center | P3 | BB |
| Clofarabine | Targazyme, Inc. | P3 | BB |
| Melphalan | M.D. Anderson Cancer Center | P2 | BB |
| Anti-Human T-Lymphocyte Immunoglobulin, Rabbit | Targazyme, Inc. | P3 | B |
+23 more in the Disease Related To Transplantation cohort
Other indications for Valganciclovir
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Cytomegalovirus Infection | — | P3 | BB · 68 |
| Lymphoproliferative Syndrome | — | P2 | B · 61 |
| Epstein-Barr Virus-Associated Lymphoproliferative Disorder | — | P2 | B · 61 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Valganciclovir in Disease Related To Transplantation. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/valganciclovir-disease-related-to-transplantation
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →